Arthur M Pappas Net Worth

The estimated Net Worth of Arthur M Pappas is at least $4.08 Milión dollars as of 23 October 2013. Arthur Pappas owns over 216,840 units of Chimerix Inc stock worth over $714,398 and over the last 12 years Arthur sold CMRX stock worth over $3,363,188.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Arthur Pappas CMRX stock SEC Form 4 insiders trading

Arthur has made over 1 trades of the Chimerix Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently Arthur sold 216,840 units of CMRX stock worth $3,363,188 on 23 October 2013.

The largest trade Arthur's ever made was selling 216,840 units of Chimerix Inc stock on 23 October 2013 worth over $3,363,188. On average, Arthur trades about 108,420 units every 0 days since 2013. As of 23 October 2013 Arthur still owns at least 830,695 units of Chimerix Inc stock.

You can see the complete history of Arthur Pappas stock trades at the bottom of the page.

What's Arthur Pappas's mailing address?

Arthur's mailing address filed with the SEC is C/O CHIMERIX, INC., 2505 MERIDIAN PARKWAY, SUITE 340, DURHAM,, NC, 27713.

Insiders trading at Chimerix Inc

Over the last 12 years, insiders at Chimerix Inc have traded over $133,441,183 worth of Chimerix Inc stock and bought 1,129,869 units worth $4,757,752 . The most active insiders traders include Patrick Machado, Pharmaceuticals, Inc. Cantex a Ernest Mario. On average, Chimerix Inc executives and independent directors trade stock every 25 days with the average trade being worth of $72,060. The most recent stock trade was executed by Michael T. Andriole on 8 August 2024, trading 1,285 units of CMRX stock currently worth $1,067.

What does Chimerix Inc do?

led by an experienced antiviral drug development team, chimerix is developing novel oral antiviral therapeutics with the potential to improve quality of life for patients in multiple settings, including transplant, oncology, acute care and global health. the company’s proprietary lipid technology has given rise to two clinical stage compounds, cmx001 and cmx157, which have demonstrated the potential for enhanced activity, bioavailability and safety compared to currently approved drugs. chimerix’s lead compound, cmx001, is a broad spectrum lipid acyclic nucleoside phosphonate that inhibits double-stranded dna (dsdna) viruses including cytomegalovirus (cmv), adenovirus, bk virus, herpes simplex virus and variola (smallpox). cmx001 has completed phase 2 clinical development for the prophylaxis of cmv and is in phase 2 development for the preemption and treatment of adenovirus infection in hematopoietic stem cell transplant (hsct) recipients. to date, more than 750 patients have been dosed

Complete history of Arthur Pappas stock trades at Chimerix Inc

Chimerix Inc executives and stock owners

Chimerix Inc executives and other stock owners filed with the SEC include:

• Michael Sherman,
  President, Chief Executive Officer, Director
• Michael Andriole,
  Chief Financial Officer, Chief Business Officer
• Michael Alrutz,
  Senior Vice President, General Counsel
• Michael A. Sherman,
  CEO, Pres & Director
• Michael T. Andriole M.B.A.,
  Chief Bus. Officer, Sec. & CFO
• Dr. Allen S. Melemed M.B.A., M.D.,
  Chief Medical Officer
• Martha Demski,
  Independent Chairman of the Board
• Patrick Machado,
  Independent Director
• Fred Middleton,
  Independent Director
• Robert Meyer,
  Independent Director
• Catherine Gilliss,
  Independent Director
• Edward Greissing,
  Independent Director
• Pratik Multani,
  Independent Director
• Dr. Joshua E. Allen,
  Chief Technology Officer of Imipridones
• Dr. Michael A. Alrutz,
  Sr. VP, Gen. Counsel & Corp. Sec.
• Michelle LaSpaluto,
  VP of Strategic Planning & Investor Relations
• Dr. Randall Lanier,
  Chief Science Officer
• Dr. Roy W. Ware,
  Chief Manufacturing & Technology Officer
• David Jakeman,
  Exec. Director of Fin. & Accounting and Principal Accounting Officer
• Michael D. Rogers,
  Chief Development Officer
• James Niedel,
  Director
• Ernest Mario,
  Director
• M Michelle Berrey,
  President and CEO
• Garrett Nichols,
  Chief Medical Officer
• John M Leonard,
  Director
• Ronald C Jr Renaud,
  Director
• James M Daly,
  Director
• Lisa Ricciardi,
  Director
• Timothy Wollaeger,
  Director
• Linda M Richardson,
  Chief Commercial Officer
• Ed Greissing,
  Director
• Victoria Vakiener,
  
• Leaf Ventures Ii, L.P. New,
  10% owner
• Venture Partners V, Lp Sand...,
  10% owner
• Venture Partners Vi Co Inve...,
  10% owner
• Rodman L Drake,
  Director
• Vii L P Canaan Partners Vii...,
  
• Leaf Ventures Ii, L.P.New L...,
  
• Kenneth I Moch,
  President and CEO
• Wende S Hutton,
  Director
• Venture Partners V, Lp Sand...,
  
• Arthur M Pappas,
  Director
• Venture Partners V, Lpsande...,
  
• Farah Champsi,
  Director
• Timothy W. Trost,
  SVP, CFO & Secretary
• Biopharma Partners Iii Lpal...,
  
• Pappas Life Science Venture...,
  
• Lisa Lynn Decker,
  
• Pharmaceuticals, Inc. Cantex,
  10% owner
• Marc D Kozin,
  
• David Jakeman,
  VP OF FINANCE AND ACCOUNTING
• Thomas J Riga,
  COO and CCO
• Allen S. Melemed,
  CHIEF MEDICAL OFFICER
• Michelle La Spaluto,
  CHIEF FINANCIAL OFFICER